Vitrolife: All Patients Included in the Clinical Study on STEEN Solution™ in the USA  
4/18/2012 10:21:46 AM

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Vitrolife (STO:VITR): In the clinical study that was begun during 2011 on STEEN Solution™ with the aim of forming a basis for sales approval in the USA, a total of 13 patients have now received transplants. The required number of patients, which was 12, has thereby been included in the study. “Even if some work remains and it is difficult to assess how the FDA will reply it is now reasonable to assume that this is a big step closer to sales approval in the most important market in the world,” says Dr Magnus Nilsson, who is responsible for Vitrolife’s transplantation area.